News

In this study, we report the efficacy, safety, and immunogenicity of BIMERVAX® in cynomolgus macaque model of SARS-CoV-2 we developed with Cynbiose. Prime-boost vaccination induces high levels of RBD-specific IgG binding and neutralizing antibodies against several SARS-CoV-2 variants, as well as a balanced Th1/Th2 cellular immune response. Remarkably, BIMERVAX® vaccination prevents SARS-CoV-2 replication in the lower respiratory tract and significantly reduces viral load in the upper respirato...

This excellence preclinical research network is dedicated to microbiome and infectious diseases research field and offers synergic expertise and large customized services in high-throughput sequencing, biomanufacturing, imaging, microfluidics, specific analyses, biomarkers, preclinical and clinical activities. Virnext brings to the Cynbiome® network its expertise in emergent and re-emergent respiratory viruses and provides a large panel of in vitro and in vivo preclinical models of infection...

Our partner IMéBIO, a company expert in modular technical environments for biotechnology and health, has delivered a mobile and autonomous BSL-3 laboratory of 45 m2 to allow us to amplify our collaborative research activities in the fight against emerging and re-emerging infectious diseases. These additional laboratory spaces will in particular make it possible to accelerate our various R&D programs carried out with our spin-off VirexpR in the field of microbiological contamination of indoo...

Virnext is very proud to have contributed with its partner Cynbiose to preclinical assessment and accelerating transfer to clinical trial of the HIPRA’s Covid-19 BIMERVAX® vaccine, recently approved by the European Medicines Agency. Virnext has been committed for several years in the development of in vitro and in vivo preclinical models of infections dedicated to the screening and evaluation of antiviral, antibody and vaccine candidates against emergent and re-emergent respiratory viruses...

Virnext and the academic laboratory VirPath announce the grant by the INPI of their patent in partnership with Signia Therapeutics for the repurposing of diltiazem as a modulator of the innate antiviral defence and its combination with current antivirals targeting SARS-CoV-2 variants.Licensed to our spin-off Signia Therapeutics this patent expands the company’s portfolio and highlights the strength of the SIGNATURA® platform for drug identification and repurposing as innovative broad-spectrum...

Licensed to our spin-off Vaxxel, the invention relates on a proprietary recombinant hMPV strain used as a versatile live-attenuated viral vaccine platform that can express several antigens of interest. Based on the Metavac® technology, Vaxxel is developing the first intranasal bivalent vaccine candidate against human Respiratory Syncytial Virus and human Metapneumovirus. This innovation is issued from a very fruitful collaboration with Dr. GuyBoivin's team LVMC at the Centre de recherche du...

This consortium is part of the partnership dynamic that we initiated in November 2020 with the Auvergne-Rhône-Alpes Region, the Lyonbiopôle competitiveness cluster and the company VirHealth by implementing the first studies in Europe to evaluate in a test chamber the performance of several air treatment devices in an atmosphere contaminated by the infectious SARS-CoV-2 virus. On the basis of the experimental results obtained and previous technical knowledge of these devices, the Auvergne-Rhôn...

VirNext provides expertise in the field of respiratory viruses (influenza, pneumoviruses, adenovirus, rhinovirus, coronaviruses and all SARS-CoV-2 variants of interest) and a large panel of technologies including egg and cell-based process of virus and vaccine antigen production, and several in vitro and in vivo preclinical models of infection. Here under is a reconstructed human airway epithelium MucilAir (Epithelix) infected by the SARS-CoV-2 B.1.617.2 Delta strain observed by confocal micr...

This study reports a biotechnological approach for the large-scale production of sialylated multivalent solid lipid microparticles (SSLMs) that can saturate hemagglutinins and prevent virus binding to host cells. This global approach combines a microbiological step leading to the production of sialylated maltodextrin chains by a metabolic engineered Escherichia coli strain, with a new in vitro enzymatic glycosylation method onto a long-chain alkyl glucoside, and the formulation of the final SSLM...

Our technological research platform VirNext is very proud of the spin-off VirexpR which has just reached a major step in its technological and strategic development plan. Thanks to its partner ASPIDA for the joint design and realization of this unique test bench in Europe which will allow VirexpR to position itself as an international reference in the management of microbiological and virological environmental pollution, and indoor air quality in confined spaces, whose health,...